Loading clinical trials...
Loading clinical trials...
Effects of Injection Tinzaparin Prophylactic Dose (4,500 IU Anti-Xa) on Thrombin Generation in Patients With Multiple Myeloma, Lymphoma Patients and Patients Hospitalized for an Acute Medical Condition.
Conditions
Interventions
Tinzaparin
Blood sample
Locations
1
France
CHU de Saint-Etienne
Saint-Etienne, France
Start Date
April 14, 2015
Primary Completion Date
May 9, 2017
Completion Date
May 9, 2017
Last Updated
May 11, 2017
NCT05139017
NCT06152575
NCT06337318
NCT06179888
NCT06263491
NCT07388563
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions